Stockysis — AI-Powered Stock News & Sentiment Analysis

HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $44

Benzinga Newsdesk www.benzinga.com Positive 80.8%

Neg 0% Neu 0% Pos 80.8%

HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $42 to $44.

Comments

No comments yet. Be the first!